Faslodex Spermiogenesis Inhibitor
Alternative Name: Antiestrogen ICI 182780; Fulvestrant
Description: Faslodex induces infertility by diluting epididymal sperm, without blocking the reproductive tract. Targets estrogen receptor-alpha, dominant in only one region of the male reproductive tract in rats, but not dogs or marmosets at non-toxic doses-- the efferent ductules. Does not target the androgen receptor or testosterone, the dominant male hormone pathway.
Product Details
Status Details
Status Details: - Active ingredient already FDA-approved and on market for the treatment of breast cancer in women. Pre-clinical proof-of-concept studies conducted for male contraceptive use.
- Active ingredient already FDA-approved and on market for the treatment of breast cancer in women. Pre-clinical proof-of-concept studies conducted for male contraceptive use.
Additional Information
References: Cho HW, Nie R, et al. (2003). The antiestrogen ICI 182, 780 induces early effects on the adult male mouse reproductive tract and long-term decreased fertility without testicular atrophy. Reprod Biol Endocrinol 1(1): 57.
Cho HW, Nie R, et al. (2003). The antiestrogen ICI 182, 780 induces early effects on the adult male mouse reproductive tract and long-term decreased fertility without testicular atrophy. Reprod Biol Endocrinol 1(1): 57.